Search for a trial

Pancreatic cancer: validation of circulating predictive biomarkers

To validate promising circulating predictive biomarkers for FOLFIRINOX response in patients with PDAC, found in our previous pilot cohort (iKnowIT study, NL65025.078.18, MEC-2018-087) and to generate a biobank of blood samples to investigate future…

Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) in metastatic pancreatic disease (REACtiVe-2 Trial)

To investigate safety and tolerability as well as the induced immune response upon MesoPher/mitazalimab combination therapy in metastasized pancreatic disease after (modified) FOLFIRINOX.

Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study.

Investigate whether perioperative mFOLFIRINOX improves overall survival compared to adjuvant mFOLFIRINOX in resectable pancreatic cancer.

Next generation sequencing in patients with pancreatic ductal adenocarcinoma (PAN-NGS).
A nationwide prospective, translational cohort study.

To determine the prevalence of actionable genetic alterations in PDAC patients <= 60 years old.